vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Century Communities, Inc. (CCS). Click either name above to swap in a different company.
Century Communities, Inc. is the larger business by last-quarter revenue ($789.7M vs $156.4M, roughly 5.0× BIOCRYST PHARMACEUTICALS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs -12.6%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -12.8%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
20th Century Animation, Inc. is an American animation studio located in Century City, Los Angeles, until its lease with Fox Corporation ended and it was relocated to the Walt Disney Studios in Burbank. Walt Disney Studios Motion Pictures distributes and markets the films produced by this studio in theatrical markets. Formed in February 1994, it is organized as a division and label of 20th Century Studios, a subsidiary of the Walt Disney Studios, and is tasked with producing animated feature-l...
BCRX vs CCS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $789.7M |
| Net Profit | — | $24.4M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | — |
| Net Margin | — | 3.1% |
| Revenue YoY | 7.5% | -12.6% |
| Net Profit YoY | — | -38.0% |
| EPS (diluted) | $0.00 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $789.7M | ||
| Q4 25 | $406.6M | $1.2B | ||
| Q3 25 | $159.4M | $980.3M | ||
| Q2 25 | $163.4M | $1.0B | ||
| Q1 25 | $145.5M | $903.2M | ||
| Q4 24 | $131.5M | $1.3B | ||
| Q3 24 | $117.1M | $1.1B | ||
| Q2 24 | $109.3M | $1.0B |
| Q1 26 | — | $24.4M | ||
| Q4 25 | $245.8M | $36.0M | ||
| Q3 25 | $12.9M | $37.4M | ||
| Q2 25 | $5.1M | $34.9M | ||
| Q1 25 | $32.0K | $39.4M | ||
| Q4 24 | $-26.8M | $102.7M | ||
| Q3 24 | $-14.0M | $83.0M | ||
| Q2 24 | $-12.7M | $83.7M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 3.8% | ||
| Q3 25 | 18.6% | 4.9% | ||
| Q2 25 | 18.2% | 4.7% | ||
| Q1 25 | 14.6% | 5.8% | ||
| Q4 24 | -3.4% | 10.6% | ||
| Q3 24 | 6.6% | 9.7% | ||
| Q2 24 | 8.0% | 10.6% |
| Q1 26 | — | 3.1% | ||
| Q4 25 | 60.5% | 2.9% | ||
| Q3 25 | 8.1% | 3.8% | ||
| Q2 25 | 3.1% | 3.5% | ||
| Q1 25 | 0.0% | 4.4% | ||
| Q4 24 | -20.4% | 8.1% | ||
| Q3 24 | -12.0% | 7.3% | ||
| Q2 24 | -11.6% | 8.1% |
| Q1 26 | $0.00 | $0.88 | ||
| Q4 25 | $1.13 | $1.21 | ||
| Q3 25 | $0.06 | $1.25 | ||
| Q2 25 | $0.02 | $1.14 | ||
| Q1 25 | $0.00 | $1.26 | ||
| Q4 24 | $-0.13 | $3.20 | ||
| Q3 24 | $-0.07 | $2.59 | ||
| Q2 24 | $-0.06 | $2.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $78.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.6B |
| Total Assets | $465.1M | $4.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | $78.2M | ||
| Q4 25 | $274.7M | $109.4M | ||
| Q3 25 | $212.9M | $130.1M | ||
| Q2 25 | $260.0M | $93.2M | ||
| Q1 25 | $295.1M | $100.3M | ||
| Q4 24 | $320.9M | $150.0M | ||
| Q3 24 | $96.8M | $149.2M | ||
| Q2 24 | $78.4M | $106.7M |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $-119.2M | $2.6B | ||
| Q3 25 | $-387.9M | $2.6B | ||
| Q2 25 | $-421.6M | $2.6B | ||
| Q1 25 | $-451.9M | $2.6B | ||
| Q4 24 | $-475.9M | $2.6B | ||
| Q3 24 | $-468.6M | $2.5B | ||
| Q2 24 | $-475.6M | $2.5B |
| Q1 26 | $465.1M | $4.5B | ||
| Q4 25 | $514.2M | $4.5B | ||
| Q3 25 | $446.4M | $4.7B | ||
| Q2 25 | $457.2M | $4.6B | ||
| Q1 25 | $480.0M | $4.6B | ||
| Q4 24 | $490.4M | $4.5B | ||
| Q3 24 | $491.3M | $4.8B | ||
| Q2 24 | $472.4M | $4.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
CCS
| Home sales revenues | $734.1M | 93% |
| Land sales and other revenues | $33.2M | 4% |
| Financial services revenues | $22.4M | 3% |
